ID

DB00202|APRD00159||

名称

Succinylcholine

描述

A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.

cas号

306-40-1

唯一标识码

J2R869A8YF

状态

solid

组

approved,

指示

Used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT)

药效学

Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is a depolarizing skeletal muscle relaxant. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Succinylcholine has no direct action on the uterus or other smooth muscle structures.

作用机制

The mechanism of action of Succinylcholine involves what appears to be a "persistent" depolarization of the neuromuscular junction. This depolarization is caused by Succinylcholine mimicking the effect of acetylcholine but without being rapidly hydrolysed by acetylcholinesterase. This depolarization leads to desensitization.

毒性

代谢

By pseudocholinesterase, to succinylmonocholine and choline.

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as acyl cholines. These are acylated derivatives of choline. Choline or 2-Hydroxy-N,N,N-trimethylethanaminium is a quaternary ammonium salt with the chemical formula (CH3)3N+(CH2)2OH.
direct-parent:Acyl cholines
kingdom:Organic compounds
superclass:Organic nitrogen compounds
class:Organonitrogen compounds
subclass:Quaternary ammonium salts
alternative-parent:Amines
alternative-parent:Carbonyl compounds
alternative-parent:Carboxylic acid esters
alternative-parent:Dicarboxylic acids and derivatives
alternative-parent:Fatty acid esters
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic cations
alternative-parent:Organic oxides
alternative-parent:Organic salts
alternative-parent:Organopnictogen compounds
alternative-parent:Tetraalkylammonium salts
substituent:Acyl choline
substituent:Aliphatic acyclic compound
substituent:Amine
substituent:Carbonyl group
substituent:Carboxylic acid derivative
substituent:Carboxylic acid ester
substituent:Dicarboxylic acid or derivatives
substituent:Fatty acid ester
substituent:Fatty acyl
substituent:Hydrocarbon derivative
substituent:Organic cation
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organic salt
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Tetraalkylammonium salt

消除途径

About 10% of the drug is excreted unchanged in the urine.

种类

Acids, Acyclic
D000144
Agents causing hyperkalemia

Alcohols
D000438
Amines
D000588
Amino Alcohols
D000605
Ammonium Compounds
D064751
Central Nervous System Depressants
D002492
Choline Derivatives

Cholinesterase substrates

Dicarboxylic Acids
D003998
Ethanolamines
D004983
Muscle Relaxants

Muscle Relaxants, Peripherally Acting Agents

Musculo-Skeletal System

Neuromuscular Agents
D009465
Neuromuscular Blocking Agents
D009466
Neuromuscular Depolarizing Agents
D009467
Neuromuscular Depolarizing Blockade

Neurotoxic agents

Nitrogen Compounds
D017672
Onium Compounds
D009861
Peripheral Nervous System Agents
D018373
Quaternary Ammonium Compounds
D000644
Succinates
D013386
Trimethyl Ammonium Compounds
D050337

盐类

DBSALT000206Succinylcholine chlorideI9L0DDD30I71-27-2YOEWQQVKRJEPAE-UHFFFAOYSA-L361.305360.158262872DBSALT003046Succinylcholine chloride dihydrate8L0S1G435E6101-15-1FFSBEIRFVXGRPR-UHFFFAOYSA-L397.33396.1793922

蛋白质结合

清除

同义词

language:english; code:; name;2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
language:english; code:; name;Dicholine succinate
language:english; code:; name;Succinocholine
language:english; code:; name;Succinoylcholine
language:english; code:; name;Succinylbischoline
language:english; code:; name;Succinyldicholine
language:english; code:; name;Suxamethonium

国际品牌

ScolineSucostrin

配送量

产品

name:Anectine
labeller:Sandoz
ndc-id:
ndc-product-code:0781-9009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-12
ended-marketing-on:2015-10-12
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous; Parenteral
fda-application-number:NDA008453
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Anectine
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-3009
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1952-08-20
ended-marketing-on:2019-05-31
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous; Parenteral
fda-application-number:NDA008453
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Anectine
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-9053
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-12
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous; Parenteral
fda-application-number:NDA008453
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Anectine
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-3411
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-06-22
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous; Parenteral
fda-application-number:NDA008453
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Anectine
labeller:Civica, Inc.
ndc-id:
ndc-product-code:72572-750
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-12-11
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous; Parenteral
fda-application-number:NDA008453
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Anectine Flopack 500mg
labeller:Glaxo Wellcome
ndc-id:
ndc-product-code:
dpd-id:00068330
ema-product-code:
ema-ma-number:
started-marketing-on:1959-12-31
ended-marketing-on:1998-11-03
dosage-form:Powder, for solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Anectine Inj 20mg/ml
labeller:Glaxo Wellcome
ndc-id:
ndc-product-code:
dpd-id:00268305
ema-product-code:
ema-ma-number:
started-marketing-on:1952-12-31
ended-marketing-on:2000-01-19
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Quelicin
labeller:Remedy Repack
ndc-id:
ndc-product-code:70518-0870
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-29
ended-marketing-on:2018-03-26
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-8065
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2006-07-10
ended-marketing-on:2006-07-10
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6629
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-31
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Hospira, Inc.
ndc-id:
ndc-product-code:0409-6970
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-06-23
ended-marketing-on:2013-08-01
dosage-form:Injection, solution
strength:100 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7146
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-31
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7026
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-31
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quelicin
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:00038172
ema-product-code:
ema-ma-number:
started-marketing-on:1952-12-31
ended-marketing-on:
dosage-form:Solution
strength:20 mg
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Quelicin
labeller:Pfizer Canada Ulc
ndc-id:
ndc-product-code:
dpd-id:00296163
ema-product-code:
ema-ma-number:
started-marketing-on:1976-12-31
ended-marketing-on:2019-04-05
dosage-form:Solution
strength:100 mg
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Quelicin Inj 20mg/ml USP
labeller:Abbott
ndc-id:
ndc-product-code:
dpd-id:00640778
ema-product-code:
ema-ma-number:
started-marketing-on:1985-12-31
ended-marketing-on:2009-12-14
dosage-form:Solution
strength:
route:Intramuscular; Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Succinylcholine
labeller:Dr.Reddy's Laboratories Inc.,
ndc-id:
ndc-product-code:43598-666
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-07
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA210698
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Cantrell Drug Company
ndc-id:
ndc-product-code:52533-067
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-12
ended-marketing-on:2017-12-06
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Cadila Healthcare Limited
ndc-id:
ndc-product-code:70771-1352
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-10
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA209467
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Renaissance Lakewood LLC
ndc-id:
ndc-product-code:49396-0152
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-10-01
ended-marketing-on:
dosage-form:Injection
strength:200 mg/10mL
route:Parenteral
fda-application-number:ANDA210231
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7166
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-20
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211432
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Renaissance Ssa, Llc
ndc-id:
ndc-product-code:70655-015
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-28
ended-marketing-on:2019-06-28
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA210231
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7167
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-10
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA210231
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:General Injectables & Vaccines, Inc.
ndc-id:
ndc-product-code:52584-377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-22
ended-marketing-on:2020-07-31
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA209467
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Amring Pharmaceuticals Inc.
ndc-id:
ndc-product-code:69918-700
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-10-04
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA210231
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Somerset Therapeutics, Llc
ndc-id:
ndc-product-code:70069-301
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-15
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Amneal Pharmaceuticals LLC
ndc-id:
ndc-product-code:70121-1581
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-20
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211432
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:HF Acquisition Co LLC, DBA HealthFirst
ndc-id:
ndc-product-code:51662-1353
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-06
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:NDA008845
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Breckenridge Pharmaceutical, Inc.
ndc-id:
ndc-product-code:51991-964
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-01
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA212638
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Liva Pharmaceuticals Limited
ndc-id:
ndc-product-code:72785-0010
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-10
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA209467
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Zydus Pharmaceuticals (USA) Inc.
ndc-id:
ndc-product-code:70710-1377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-10
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA209467
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Nivagen Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:75834-151
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-05-20
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211625
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Indoco Remedies Limited
ndc-id:
ndc-product-code:14445-407
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-31
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA214308
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Camber Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:31722-981
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-05-04
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA213810
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Gland Pharma Limited
ndc-id:
ndc-product-code:68083-450
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-16
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA214246
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:General Injectables & Vaccines, Inc.
ndc-id:
ndc-product-code:52584-097
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-11-21
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211432
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:BluePoint Laboratories
ndc-id:
ndc-product-code:68001-448
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-08-31
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211432
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Hikma Pharmaceuticals USA Inc.
ndc-id:
ndc-product-code:0143-9338
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-06-12
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA213229
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:General Injectables and Vaccines, Inc.
ndc-id:
ndc-product-code:52584-964
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-10-21
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA212638
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:STI Pharma LLC
ndc-id:
ndc-product-code:54879-037
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-11-03
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA214308
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Amphastar Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:0548-9801
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-12-01
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA213432
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7221
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-15
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intramuscular; Intravenous
fda-application-number:ANDA211589
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Succinylcholine Chloride Injection USP
labeller:Mylan Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02062232
ema-product-code:
ema-ma-number:
started-marketing-on:1996-11-12
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Succinylcholine Chloride Injection USP
labeller:Teligent Ou
ndc-id:
ndc-product-code:
dpd-id:02422336
ema-product-code:
ema-ma-number:
started-marketing-on:2014-09-30
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Succinylcholine Chloride Injection, USP
labeller:Dr Reddy's Laboratories Ltd
ndc-id:
ndc-product-code:
dpd-id:02501783
ema-product-code:
ema-ma-number:
started-marketing-on:2020-09-29
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Succinylcholine Chloride Injection, USP 20mg/ml
labeller:Alveda Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02300419
ema-product-code:
ema-ma-number:
started-marketing-on:2012-09-13
ended-marketing-on:
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Anectine
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Anectine
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Anectine
ingredients:Succinylcholine
name:Anectine
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Succinylcholine Chloride
ingredients:Succinylcholine
name:Anectine
ingredients:Succinylcholine
name:Anectine Inj 20mg/ml
ingredients:Succinylcholine
name:Quelicin Inj 20mg/ml USP
ingredients:Succinylcholine
name:Anectine Flopack 500mg
ingredients:Succinylcholine
name:Succinylcholine Chloride Injection USP
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Quelicin
ingredients:Succinylcholine
name:Succinylcholine Chloride Injection, USP 20mg/ml
ingredients:Succinylcholine
name:Succinylcholine Chloride Injection USP
ingredients:Succinylcholine
name:Succinylcholine Chloride Injection, USP
ingredients:Succinylcholine

包装者

name:Hospira Inc.
url:http://www.hospira.com
name:Pharmedium
url:http://www.pharmedium.com
name:Sandoz
url:http://www.sandoz.ca
name:Strides Arcolab Limited
url:http://www.stridesarco.com

生产者

generic:否; url:; name;Sandoz canada inc
generic:否; url:; name;Hospira inc
generic:是; url:; name;International medication systems ltd
generic:是; url:; name;Organon usa inc
generic:否; url:; name;Apothecon inc div bristol myers squibb

价格

Quelicin 100 mg/ml vial
1.2(单位：USD）
ml
Succinylcholine-ns 140 mg/7 ml
2.08(单位：USD）
ml
Quelicin 20 mg/ml vial
0.22(单位：USD）
ml

受影响的生物体

Humans and other mammals

剂量

form:Injection, solution
route:Intramuscular; Intravenous; Parenteral
strength:20 mg/1mL
form:Powder, for solution
route:Intravenous
strength:
form:Liquid
route:Intravenous
strength:
form:Solution
route:Intravenous
strength:40 mg/ml
form:Injection, solution
route:Parenteral
strength:0.1 g/5ml
form:Injection
route:
strength:2 %
form:Injection, solution
route:Intravenous; Parenteral
strength:100 MG/2ML
form:Solution
route:Intravenous
strength:500 mg/10ml
form:Injection, solution
route:Intramuscular; Intravenous
strength:100 mg/1mL
form:Injection, solution
route:Intramuscular; Intravenous
strength:20 mg/1mL
form:Solution
route:Intravenous
strength:100 mg
form:Solution
route:Intravenous
strength:20 mg
form:Solution
route:Intramuscular; Intravenous
strength:
form:Injection, powder, for solution
route:
strength:500 mg
form:Injection
route:Intramuscular; Intravenous
strength:20 mg/1mL
form:Injection
route:Parenteral
strength:200 mg/10mL
form:Injection, solution
route:Intravenous
strength:20 mg/1mL
form:Solution
route:Intravenous
strength:
form:Injection, solution
route:
strength:500 mg/10mL
form:Injection, solution
route:Parenteral
strength:10 mg/ml
form:Injection
route:
strength:100 mg/2ml

atc代码

Choline derivatives
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
MUSCLE RELAXANTS
MUSCULO-SKELETAL SYSTEM

fda标签

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00202.pdf?1265922737

专利

食物相互作用

药物相互作用

DB00921
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00366
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00470
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00450
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00956
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DB00557
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00653
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium sulfate.
DB01403
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00765
Succinylcholine may increase the sedative activities of Metyrosine.
DB01017
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00370
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00486
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB01173
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB09117
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB08883
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00413
Succinylcholine may increase the sedative activities of Pramipexole.
DB00268
Succinylcholine may increase the sedative activities of Ropinirole.
DB05271
Succinylcholine may increase the sedative activities of Rotigotine.
DB06201
The risk or severity of adverse effects can be increased when Rufinamide is combined with Succinylcholine.
DB09072
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB09034
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB06204
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB01041
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00425
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00295
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Morphine.
DB00318
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Codeine.
DB00327
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Hydromorphone.
DB00454
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meperidine.
DB00497
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxycodone.
DB00611
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Butorphanol.
DB00647
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextropropoxyphene.
DB00652
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Pentazocine.
DB00704
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.
DB00708
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Sufentanil.
DB00802
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alfentanil.
DB00813
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Fentanyl.
DB00844
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nalbuphine.
DB00854
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levorphanol.
DB00899
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Remifentanil.
DB01081
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diphenoxylate.
DB01192
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Oxymorphone.
DB01209
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dezocine.
DB01227
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Levacetylmethadol.
DB01433
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Methadyl acetate.
DB01450
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydroetorphine.
DB01452
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Diamorphine.
DB01459
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Bezitramide.
DB01466
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ethylmorphine.
DB01497
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Etorphine.
DB01529
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextromoramide.
DB01531
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Desomorphine.
DB01535
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Carfentanil.
DB01551
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydrocodeine.
DB01555
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alphacetylmethadol.
DB01565
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydromorphine.
DB06738
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ketobemidone.
DB08861
The risk or severity of bradycardia can be increased when Succinylcholine is combined with DPDPE.
DB09174
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Lofentanil.
DB09272
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Eluxadoline.
DB11130
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Opium.
DB11609
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Normethadone.
DB12492
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Piritramide.
DB13160
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Alphaprodine.
DB13454
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Nicomorphine.
DB13478
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meptazinol.
DB13605
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenoperidine.
DB13606
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Phenazocine.
DB13787
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Tilidine.
DB15360
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Carfentanil, C-11.
DB15465
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Benzhydrocodone.
DB01408
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Bambuterol.
DB00314
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Capreomycin.
DB00042
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum Toxin Type B.
DB00083
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type A.
DB00091
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.
DB00254
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Doxycycline.
DB00256
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lymecycline.
DB00319
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Piperacillin.
DB00452
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Framycetin.
DB00453
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Clomocycline.
DB00468
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinine.
DB00512
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Vancomycin.
DB00560
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tigecycline.
DB00595
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Oxytetracycline.
DB00608
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Chloroquine.
DB00618
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Demeclocycline.
DB00657
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Mecamylamine.
DB00684
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tobramycin.
DB00759
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tetracycline.
DB00798
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Gentamicin.
DB00903
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Etacrynic acid.
DB00908
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinidine.
DB00931
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Metacycline.
DB00955
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Netilmicin.
DB00994
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neomycin.
DB01082
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Streptomycin.
DB01111
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Colistimethate.
DB01172
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Kanamycin.
DB01301
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Rolitetracycline.
DB01377
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium oxide.
DB01378
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium cation.
DB01421
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Paromomycin.
DB01627
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lincomycin.
DB03615
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Ribostamycin.
DB04263
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Geneticin.
DB04626
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Apramycin.
DB04729
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Gentamicin C1a.
DB04808
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Neamine.
DB06696
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Arbekacin.
DB06827
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Viomycin.
DB08437
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Puromycin.
DB09104
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium hydroxide.
DB09281
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium trisilicate.
DB09407
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium chloride.
DB09409
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium acetate tetrahydrate.
DB09481
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium carbonate.
DB11110
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium citrate.
DB11189
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium glycinate.
DB11230
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium Aluminum Silicate.
DB11512
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Dihydrostreptomycin.
DB11520
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Hygromycin B.
DB12604
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Sisomicin.
DB12615
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Plazomicin.
DB13249
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium silicate.
DB13264
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Penimepicycline.
DB13359
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium aspartate.
DB13540
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Isepamicin.
DB13749
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium gluconate.
DB13786
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium orotate.
DB13862
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium phosphate.
DB13996
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium acetate.
DB01219
The therapeutic efficacy of Dantrolene can be increased when used in combination with Succinylcholine.
DB14077
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium stearate.
DB00803
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Colistin.
DB00531
The serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.
DB00780
Phenelzine may increase the neuromuscular blocking activities of Succinylcholine.
DB00333
The risk or severity of adverse effects can be increased when Methadone is combined with Succinylcholine.
DB01035
The metabolism of Succinylcholine can be decreased when combined with Procainamide.
DB00082
The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.
DB00358
The metabolism of Succinylcholine can be decreased when combined with Mefloquine.
DB00382
The metabolism of Succinylcholine can be decreased when combined with Tacrine.
DB00515
The metabolism of Succinylcholine can be decreased when combined with Cisplatin.
DB00527
The metabolism of Succinylcholine can be decreased when combined with Cinchocaine.
DB00545
The metabolism of Succinylcholine can be decreased when combined with Pyridostigmine.
DB00585
The metabolism of Succinylcholine can be decreased when combined with Nizatidine.
DB00674
The metabolism of Succinylcholine can be decreased when combined with Galantamine.
DB00677
The metabolism of Succinylcholine can be decreased when combined with Isoflurophate.
DB00711
The metabolism of Succinylcholine can be decreased when combined with Diethylcarbamazine.
DB00888
The metabolism of Succinylcholine can be decreased when combined with Mechlorethamine.
DB00944
The metabolism of Succinylcholine can be decreased when combined with Demecarium.
DB00981
The metabolism of Succinylcholine can be decreased when combined with Physostigmine.
DB00989
The metabolism of Succinylcholine can be decreased when combined with Rivastigmine.
DB01010
The metabolism of Succinylcholine can be decreased when combined with Edrophonium.
DB01043
The metabolism of Succinylcholine can be decreased when combined with Memantine.
DB01122
The metabolism of Succinylcholine can be decreased when combined with Ambenonium.
DB01381
The metabolism of Succinylcholine can be decreased when combined with Ginkgo biloba.
DB01400
The metabolism of Succinylcholine can be decreased when combined with Neostigmine.
DB02365
The metabolism of Succinylcholine can be decreased when combined with 1,10-Phenanthroline.
DB04572
The metabolism of Succinylcholine can be decreased when combined with Thiotepa.
DB04864
The metabolism of Succinylcholine can be decreased when combined with Huperzine A.
DB04892
The metabolism of Succinylcholine can be decreased when combined with Phenserine.
DB05386
The metabolism of Succinylcholine can be decreased when combined with Regramostim.
DB06692
The metabolism of Succinylcholine can be decreased when combined with Aprotinin.
DB06756
The metabolism of Succinylcholine can be decreased when combined with Glycine betaine.
DB06774
The metabolism of Succinylcholine can be decreased when combined with Capsaicin.
DB11390
The metabolism of Succinylcholine can be decreased when combined with Coumaphos.
DB11397
The metabolism of Succinylcholine can be decreased when combined with Dichlorvos.
DB11412
The metabolism of Succinylcholine can be decreased when combined with Fenthion.
DB11473
The metabolism of Succinylcholine can be decreased when combined with Metrifonate.
DB12482
The metabolism of Succinylcholine can be decreased when combined with Acotiamide.
DB13058
The metabolism of Succinylcholine can be decreased when combined with Methanesulfonyl Fluoride.
DB13495
The metabolism of Succinylcholine can be decreased when combined with Paraoxon.
DB13503
The metabolism of Succinylcholine can be decreased when combined with Tyrothricin.
DB13668
The metabolism of Succinylcholine can be decreased when combined with Ipidacrine.
DB13694
The metabolism of Succinylcholine can be decreased when combined with Distigmine.
DB14031
The metabolism of Succinylcholine can be decreased when combined with Tretamine.
DB15317
The metabolism of Succinylcholine can be decreased when combined with Posiphen.
DB00392
The metabolism of Profenamine can be decreased when combined with Succinylcholine.
DB00391
The metabolism of Sulpiride can be decreased when combined with Succinylcholine.
DB00477
The metabolism of Chlorpromazine can be decreased when combined with Succinylcholine.
DB00483
The metabolism of Gallamine triethiodide can be decreased when combined with Succinylcholine.
DB00508
The metabolism of Triflupromazine can be decreased when combined with Succinylcholine.
DB00721
The metabolism of Procaine can be decreased when combined with Succinylcholine.
DB00805
The metabolism of Minaprine can be decreased when combined with Succinylcholine.
DB00843
The metabolism of Donepezil can be decreased when combined with Succinylcholine.
DB00941
The metabolism of Hexafluronium can be decreased when combined with Succinylcholine.
DB01199
The metabolism of Tubocurarine can be decreased when combined with Succinylcholine.
DB01221
The metabolism of Ketamine can be decreased when combined with Succinylcholine.
DB01245
The metabolism of Decamethonium can be decreased when combined with Succinylcholine.
DB01337
The metabolism of Pancuronium can be decreased when combined with Succinylcholine.
DB01338
The metabolism of Pipecuronium can be decreased when combined with Succinylcholine.
DB02845
The metabolism of Succinylcholine can be decreased when combined with Methylphosphinic Acid.
DB00898
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00972
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00484
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.
DB00176
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluvoxamine.
DB00215
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Citalopram.
DB00476
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Duloxetine.
DB00656
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trazodone.
DB00715
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paroxetine.
DB01104
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sertraline.
DB01105
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sibutramine.
DB01149
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nefazodone.
DB01175
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Escitalopram.
DB04832
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zimelidine.
DB04884
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dapoxetine.
DB04896
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Milnacipran.
DB06700
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desvenlafaxine.
DB06731
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Seproxetine.
DB08918
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levomilnacipran.
DB08953
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Indalpine.
DB12693
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ritanserin.
DB13233
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alaproclate.
DB00511
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Acetyldigitoxin.
DB01078
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Deslanoside.
DB01092
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Ouabain.
DB01396
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Digitoxin.
DB12843
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Oleandrin.
DB13240
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Cymarin.
DB13307
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Proscillaridin.
DB13467
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Lanatoside C.
DB13537
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Gitoformate.
DB13756
The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Peruvoside.
DB00209
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
DB00219
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.
DB00245
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
DB00280
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
DB00321
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DB00332
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.
DB00340
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Metixene.
DB00342
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.
DB00354
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.
DB00376
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
DB00383
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.
DB00387
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.
DB00424
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
DB00434
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DB00458
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
DB00462
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.
DB00496
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
DB00505
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.
DB00517
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.
DB00540
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
DB00543
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
DB00572
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Atropine.
DB00670
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.
DB00725
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.
DB00767
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.
DB00777
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.
DB00782
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
DB00804
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
DB00810
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.
DB00907
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DB00934
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
DB00940
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
DB00942
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.
DB00986
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
DB01036
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
DB01062
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
DB01142
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DB01148
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
DB01151
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DB01231
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.
DB01409
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tiotropium.
DB01591
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
DB01625
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.
DB04843
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.
DB06153
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
DB06702
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
DB06787
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.
DB08801
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.
DB08897
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
DB08997
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
DB09076
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium.
DB09167
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.
DB09262
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.
DB09300
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.
DB11235
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.
DB11315
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
DB11855
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.
DB12086
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.
DB12278
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.
DB12526
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Batefenterol.
DB12554
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
DB13252
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.
DB13254
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Prifinium.
DB13351
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.
DB13369
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Benzilone.
DB13380
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.
DB13413
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Phenglutarimide.
DB13448
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Mazaticol.
DB13468
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Etybenzatropine.
DB13507
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Poldine.
DB13542
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Bevonium.
DB13581
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Rociverine.
DB13619
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.
DB13636
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Etanautine.
DB13666
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.
DB13678
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.
DB13695
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Penthienate.
DB13720
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.
DB13738
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.
DB13759
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.
DB13769
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.
DB13844
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
DB13850
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Timepidium.
DB00622
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.
DB09089
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.
DB13500
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Otilonium.
DB09007
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.
DB01198
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zopiclone.
DB00150
The risk or severity of adverse effects can be increased when Tryptophan is combined with Succinylcholine.
DB00182
The risk or severity of adverse effects can be increased when Amphetamine is combined with Succinylcholine.
DB00186
The risk or severity of adverse effects can be increased when Lorazepam is combined with Succinylcholine.
DB00189
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Succinylcholine.
DB00206
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Reserpine.
DB00216
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eletriptan.
DB00228
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Enflurane.
DB00231
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Temazepam.
DB00234
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Reboxetine.
DB00237
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butabarbital.
DB00241
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butalbital.
DB00247
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methysergide.
DB00248
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cabergoline.
DB00273
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Topiramate.
DB00283
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clemastine.
DB00285
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Venlafaxine.
DB00289
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Atomoxetine.
DB00292
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etomidate.
DB00306
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Talbutal.
DB00312
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pentobarbital.
DB00313
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valproic acid.
DB00315
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zolmitriptan.
DB00320
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dihydroergotamine.
DB00323
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tolcapone.
DB00334
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Olanzapine.
DB00341
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cetirizine.
DB00344
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Protriptyline.
DB00347
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimethadione.
DB00349
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clobazam.
DB00356
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorzoxazone.
DB00363
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clozapine.
DB00371
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Meprobamate.
DB00372
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiethylperazine.
DB00377
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Palonosetron.
DB00404
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alprazolam.
DB00405
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexbrompheniramine.
DB00408
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Loxapine.
DB00409
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Remoxipride.
DB00416
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metocurine iodide.
DB00418
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Secobarbital.
DB00420
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Promazine.
DB00423
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methocarbamol.
DB00427
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triprolidine.
DB00433
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prochlorperazine.
DB00463
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metharbital.
DB00474
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methohexital.
DB00475
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlordiazepoxide.
DB00494
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Entacapone.
DB00514
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dextromethorphan.
DB00532
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mephenytoin.
DB00546
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Adinazolam.
DB00555
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lamotrigine.
DB00564
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbamazepine.
DB00565
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cisatracurium.
DB00574
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fenfluramine.
DB00579
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mazindol.
DB00589
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lisuride.
DB00593
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethosuximide.
DB00599
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiopental.
DB00601
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Linezolid.
DB00604
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cisapride.
DB00614
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Furazolidone.
DB00617
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paramethadione.
DB00623
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluphenazine.
DB00625
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Efavirenz.
DB00628
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clorazepic acid.
DB00633
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexmedetomidine.
DB00645
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dyclonine.
DB00660
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metaxalone.
DB00662
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimethobenzamide.
DB00669
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sumatriptan.
DB00679
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thioridazine.
DB00680
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Moricizine.
DB00683
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Midazolam.
DB00690
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flurazepam.
DB00696
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergotamine.
DB00697
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tizanidine.
DB00714
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Apomorphine.
DB00726
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trimipramine.
DB00728
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rocuronium.
DB00732
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Atracurium besylate.
DB00734
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Risperidone.
DB00737
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Meclizine.
DB00740
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Riluzole.
DB00747
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Scopolamine.
DB00748
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbinoxamine.
DB00752
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tranylcypromine.
DB00753
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Isoflurane.
DB00754
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethotoin.
DB00757
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dolasetron.
DB00771
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clidinium.
DB00776
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxcarbazepine.
DB00794
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Primidone.
DB00801
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Halazepam.
DB00818
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propofol.
DB00819
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acetazolamide.
DB00829
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diazepam.
DB00831
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trifluoperazine.
DB00832
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phensuximide.
DB00835
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brompheniramine.
DB00837
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Progabide.
DB00842
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxazepam.
DB00849
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methylphenobarbital.
DB00850
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perphenazine.
DB00865
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzphetamine.
DB00875
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flupentixol.
DB00889
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Granisetron.
DB00897
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triazolam.
DB00904
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ondansetron.
DB00906
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tiagabine.
DB00909
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zonisamide.
DB00918
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Almotriptan.
DB00933
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mesoridazine.
DB00937
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diethylpropion.
DB00949
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Felbamate.
DB00952
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naratriptan.
DB00953
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rizatriptan.
DB00962
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zaleplon.
DB00967
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desloratadine.
DB00969
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alosetron.
DB00980
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ramelteon.
DB00985
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dimenhydrinate.
DB00996
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gabapentin.
DB00998
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Frovatriptan.
DB01018
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Guanfacine.
DB01028
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methoxyflurane.
DB01037
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Selegiline.
DB01049
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergoloid mesylate.
DB01063
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acetophenazine.
DB01065
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melatonin.
DB01068
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clonazepam.
DB01069
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Promethazine.
DB01075
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diphenhydramine.
DB01080
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vigabatrin.
DB01100
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pimozide.
DB01107
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methyprylon.
DB01114
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorpheniramine.
DB01121
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenacemide.
DB01135
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Doxacurium.
DB01154
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiamylal.
DB01156
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bupropion.
DB01159
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Halothane.
DB01168
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Procarbazine.
DB01171
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Moclobemide.
DB01174
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenobarbital.
DB01176
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyclizine.
DB01178
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlormezanone.
DB01186
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pergolide.
DB01189
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Desflurane.
DB01200
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromocriptine.
DB01202
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levetiracetam.
DB01215
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Estazolam.
DB01224
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Quetiapine.
DB01226
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mivacurium.
DB01235
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levodopa.
DB01236
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sevoflurane.
DB01238
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aripiprazole.
DB01239
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorprothixene.
DB01242
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clomipramine.
DB01246
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alimemazine.
DB01247
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Isocarboxazid.
DB01253
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ergometrine.
DB01267
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Paliperidone.
DB01323
The risk or severity of adverse effects can be increased when Succinylcholine is combined with St. John's Wort.
DB01336
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metocurine.
DB01339
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vecuronium.
DB01351
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amobarbital.
DB01352
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aprobarbital.
DB01353
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butobarbital.
DB01354
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Heptabarbital.
DB01355
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hexobarbital.
DB01367
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rasagiline.
DB01392
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Yohimbine.
DB01437
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Glutethimide.
DB01440
The risk or severity of adverse effects can be increased when Succinylcholine is combined with gamma-Hydroxybutyric acid.
DB01442
The risk or severity of adverse effects can be increased when Succinylcholine is combined with MMDA.
DB01445
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bufotenine.
DB01454
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Midomafetamine.
DB01463
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fencamfamin.
DB01472
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 4-Methoxyamphetamine.
DB01483
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Barbital.
DB01484
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01488
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dimethyltryptamine.
DB01489
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Camazepam.
DB01495
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dichloralphenazone.
DB01501
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Difenoxin.
DB01509
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tenamfetamine.
DB01511
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Delorazepam.
DB01534
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorhexadol.
DB01544
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flunitrazepam.
DB01545
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethyl loflazepate.
DB01547
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Drotebanol.
DB01553
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cloxazolam.
DB01558
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromazepam.
DB01559
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clotiazepam.
DB01560
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cathinone.
DB01563
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chloral hydrate.
DB01567
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fludiazepam.
DB01577
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metamfetamine.
DB01580
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxprenolol.
DB01587
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ketazolam.
DB01588
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prazepam.
DB01589
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Quazepam.
DB01594
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cinolazepam.
DB01595
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nitrazepam.
DB01608
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Periciazine.
DB01614
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acepromazine.
DB01615
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aceprometazine.
DB01616
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alverine.
DB01618
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Molindone.
DB01621
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pipotiazine.
DB01622
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thioproperazine.
DB01623
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiothixene.
DB01624
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zuclopenthixol.
DB01626
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pargyline.
DB01954
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rolipram.
DB02207
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 7-Nitroindazole.
DB02234
The risk or severity of adverse effects can be increased when Succinylcholine is combined with S-Ethylisothiourea.
DB02852
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Domoic Acid.
DB02959
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxitriptan.
DB03575
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phencyclidine.
DB04017
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clorgiline.
DB04165
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valpromide.
DB04325
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenethylamine.
DB04599
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aniracetam.
DB04818
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iproniazid.
DB04819
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methapyrilene.
DB04820
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nialamide.
DB04821
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nomifensine.
DB04827
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Urethane.
DB04829
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lysergic acid diethylamide.
DB04833
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methaqualone.
DB04834
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rapacuronium.
DB04836
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amineptine.
DB04841
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flunarizine.
DB04871
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lorcaserin.
DB04872
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Osanetant.
DB04885
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cilansetron.
DB04888
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bifeprunox.
DB04903
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pagoclone.
DB04908
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Flibanserin.
DB04917
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Renzapride.
DB04946
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iloperidone.
DB04953
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ezogabine.
DB05227
The risk or severity of adverse effects can be increased when Succinylcholine is combined with APD791.
DB05232
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetrodotoxin.
DB05246
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methsuximide.
DB05316
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pimavanserin.
DB05541
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brivaracetam.
DB05542
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naronapride.
DB05562
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naluzotan.
DB05607
The risk or severity of adverse effects can be increased when Succinylcholine is combined with PRX-08066.
DB05687
The risk or severity of adverse effects can be increased when Succinylcholine is combined with BL-1020.
DB05710
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gantacurium.
DB06016
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cariprazine.
DB06077
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lumateperone.
DB06109
The risk or severity of adverse effects can be increased when Succinylcholine is combined with YKP-1358.
DB06144
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sertindole.
DB06148
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mianserin.
DB06216
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Asenapine.
DB06218
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lacosamide.
DB06264
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tolperisone.
DB06282
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Levocetirizine.
DB06283
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ziconotide.
DB06288
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amisulpride.
DB06458
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Remacemide.
DB06470
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clomethiazole.
DB06512
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Deramciclane.
DB06527
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tramiprosate.
DB06529
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ocinaplon.
DB06554
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gaboxadol.
DB06579
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Adipiplon.
DB06582
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dextofisopam.
DB06594
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Agomelatine.
DB06654
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Safinamide.
DB06660
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Saredutant.
DB06678
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Esmirtazapine.
DB06684
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vilazodone.
DB06690
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nitrous oxide.
DB06691
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mepyramine.
DB06701
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dexmethylphenidate.
DB06716
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fospropofol.
DB06753
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Triclofos.
DB06770
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzyl alcohol.
DB06797
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mebutamate.
DB08059
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Wortmannin.
DB08329
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sulthiame.
DB08550
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DB08810
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cinitapride.
DB08811
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tofisopam.
DB08815
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lurasidone.
DB08839
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Serotonin.
DB08872
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gabapentin enacarbil.
DB08892
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Arbaclofen Placarbil.
DB08910
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pomalidomide.
DB08922
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perospirone.
DB08927
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amperozide.
DB08954
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ifenprodil.
DB08960
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hexamethonium.
DB08986
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etifoxine.
DB08992
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eperisone.
DB08996
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dimetacrine.
DB09000
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyamemazine.
DB09001
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Barbexaclone.
DB09011
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Beclamide.
DB09014
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Captodiame.
DB09016
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butriptyline.
DB09017
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brotizolam.
DB09021
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzoctamine.
DB09023
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benactyzine.
DB09068
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vortioxetine.
DB09071
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tasimelteon.
DB09118
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Stiripentol.
DB09119
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eslicarbazepine acetate.
DB09128
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brexpiprazole.
DB09166
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etizolam.
DB09184
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Edivoxetine.
DB09185
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Viloxazine.
DB09186
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nisoxetine.
DB09187
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lortalamine.
DB09190
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Talopram.
DB09194
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etoperidone.
DB09223
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Blonanserin.
DB09224
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melperone.
DB09225
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zotepine.
DB09226
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brilaroxazine.
DB09241
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methylene blue.
DB09243
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hydracarbazine.
DB09244
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pirlindole.
DB09245
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Toloxatone.
DB09246
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benmoxin.
DB09247
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iproclozide.
DB09248
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mebanazine.
DB09249
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Octamoxin.
DB09250
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pheniprazine.
DB09251
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenoxypropazine.
DB09252
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pivhydrazine.
DB09253
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Safrazine.
DB09254
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Caroxazone.
DB09286
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pipamperone.
DB09289
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tianeptine.
DB09290
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ramosetron.
DB09307
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxaprotiline.
DB11156
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pyrantel.
DB11371
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alfaxalone.
DB11376
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Azaperone.
DB11400
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Doramectin.
DB11428
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Medetomidine.
DB11477
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Xylazine.
DB11540
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propiopromazine.
DB11543
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Romifidine.
DB11549
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tiletamine.
DB11552
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tricaine.
DB11555
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zolazepam.
DB11556
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Detomidine.
DB11582
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiocolchicoside.
DB11664
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Psilocybin.
DB11675
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mosapride.
DB11686
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iferanserin.
DB11699
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tropisetron.
DB11755
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetrahydrocannabivarin.
DB11859
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brexanolone.
DB11868
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Etiracetam.
DB11889
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lanicemine.
DB11957
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Idalopirdine.
DB12071
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vabicaserin.
DB12093
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetrahydropalmatine.
DB12105
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Imagabalin.
DB12110
The risk or severity of adverse effects can be increased when Succinylcholine is combined with m-Chlorophenylpiperazine.
DB12111
The risk or severity of adverse effects can be increased when Succinylcholine is combined with MK-212.
DB12131
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinpocetine.
DB12163
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sarpogrelate.
DB12177
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eplivanserin.
DB12184
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gepirone.
DB12229
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cerlapirdine.
DB12273
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ecopipam.
DB12308
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eltanolone.
DB12327
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Salvinorin A.
DB12338
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carisbamate.
DB12361
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Piclozotan.
DB12395
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Esreboxetine.
DB12401
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromperidol.
DB12427
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Orvepitant.
DB12465
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ketanserin.
DB12518
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Raclopride.
DB12537
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benzodiazepine.
DB12576
The risk or severity of adverse effects can be increased when Succinylcholine is combined with AZD-3043.
DB12590
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Indiplon.
DB12661
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Urapidil.
DB12710
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perazine.
DB12725
The risk or severity of adverse effects can be increased when Succinylcholine is combined with TD-8954.
DB12833
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tandospirone.
DB12867
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Benperidol.
DB12883
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eltoprazine.
DB12930
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Opipramol.
DB12951
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pivagabine.
DB12958
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Prothipendyl.
DB12989
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Neosaxitoxin.
DB13014
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hypericin.
DB13025
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tiapride.
DB13082
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nefiracetam.
DB13099
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valnoctamide.
DB13114
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Amitriptylinoxide.
DB13213
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Butaperazine.
DB13219
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Medifoxamine.
DB13221
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Apronalide.
DB13225
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dibenzepin.
DB13234
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Propanidid.
DB13246
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Quinupramine.
DB13253
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Proxibarbal.
DB13256
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clothiapine.
DB13273
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Sultopride.
DB13295
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Atracurium.
DB13303
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Febarbamate.
DB13323
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trichloroethylene.
DB13324
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tetrazepam.
DB13331
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pyrithyldione.
DB13335
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pinazepam.
DB13352
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Deanol.
DB13354
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenprobamate.
DB13357
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Styramate.
DB13362
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pheneturide.
DB13370
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromisoval.
DB13377
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinbarbital.
DB13382
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Chlorproethazine.
DB13384
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Melitracen.
DB13396
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Neocitrullamon.
DB13402
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Acetylglycinamide chloral hydrate.
DB13403
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxypertine.
DB13411
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lofepramine.
DB13414
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fenyramidol.
DB13420
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiazinam.
DB13437
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Medazepam.
DB13455
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Phenibut.
DB13457
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxaflozane.
DB13496
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iprindole.
DB13505
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Emepronium.
DB13520
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Metergoline.
DB13522
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mebicar.
DB13523
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Veralipride.
DB13534
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gedocarnil.
DB13541
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Iprazochrome.
DB13550
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bifemelane.
DB13552
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trifluperidol.
DB13554
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Moperone.
DB13557
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiopropazate.
DB13572
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Emylcamate.
DB13577
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Allobarbital.
DB13584
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gallamine.
DB13588
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naftidrofuryl.
DB13598
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Diethyl ether.
DB13601
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxiracetam.
DB13623
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fabomotizole.
DB13642
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pridinol.
DB13643
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Loprazolam.
DB13648
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alcuronium.
DB13662
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Hexapropymate.
DB13665
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluanisone.
DB13676
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mosapramine.
DB13687
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Niaprazine.
DB13690
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinyl ether.
DB13733
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Methylpentynol.
DB13737
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyclobarbital.
DB13745
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fazadinium bromide.
DB13754
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Mephenoxalone.
DB13770
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Vinylbital.
DB13782
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Imipramine oxide.
DB13784
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dixyrazine.
DB13791
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Penfluridol.
DB13799
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ethadione.
DB13805
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Reposal.
DB13817
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Carbromal.
DB13837
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Doxefazepam.
DB13841
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Clopenthixol.
DB13872
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lormetazepam.
DB13875
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Harmaline.
DB13876
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Brofaromine.
DB13940
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB13948
The risk or severity of adverse effects can be increased when Succinylcholine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB13984
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cyclopropane.
DB13993
The risk or severity of adverse effects can be increased when Succinylcholine is combined with MRK-409.
DB14010
The risk or severity of adverse effects can be increased when Succinylcholine is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14028
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Nordazepam.
DB14050
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cannabidivarin.
DB14185
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aripiprazole lauroxil.
DB14575
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Eslicarbazepine.
DB14651
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perphenazine enanthate.
DB14672
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Oxazepam acetate.
DB14715
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Cinazepam.
DB14718
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pyrazolam.
DB14719
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bentazepam.
DB14754
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Solriamfetol.
DB15203
The risk or severity of adverse effects can be increased when Succinylcholine is combined with JNJ-26489112.
DB00866
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Alprenolol.
DB00960
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pindolol.
DB01359
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Penbutolol.
DB04842
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluspirilene.
DB06446
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dotarizine.
DB11951
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lemborexant.
DB00751
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Epinastine.
DB01356
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lithium cation.
DB00214
Torasemide may decrease the neuromuscular blocking activities of Succinylcholine.
DB00887
Bumetanide may decrease the neuromuscular blocking activities of Succinylcholine.
DB02925
Piretanide may decrease the neuromuscular blocking activities of Succinylcholine.
DB08961
Azosemide may decrease the neuromuscular blocking activities of Succinylcholine.
DB00252
The therapeutic efficacy of Phenytoin can be decreased when used in combination with Succinylcholine.
DB01320
The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Succinylcholine.
DB00180
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Flunisolide.
DB00394
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Beclomethasone dipropionate.
DB00443
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Betamethasone.
DB00588
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone propionate.
DB00591
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocinolone acetonide.
DB00620
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Triamcinolone.
DB00635
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisone.
DB00687
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fludrocortisone.
DB00741
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone.
DB00860
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone.
DB00959
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone.
DB01108
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Trilostane.
DB01222
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Budesonide.
DB01234
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone.
DB01285
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Corticotropin.
DB01380
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cortisone acetate.
DB01384
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Paramethasone.
DB01410
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Ciclesonide.
DB04630
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Aldosterone.
DB08906
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone furoate.
DB08970
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluprednidene.
DB09091
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Tixocortol.
DB09378
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluprednisolone.
DB09383
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Meprednisone.
DB11487
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone isonicotinate.
DB11529
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Melengestrol.
DB11921
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Deflazacort.
DB13003
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cortivazol.
DB13208
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednylidene.
DB13223
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocortin.
DB13491
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluperolone.
DB13843
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cloprednol.
DB13856
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluclorolone.
DB13867
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluticasone.
DB14512
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Mometasone furoate.
DB14539
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone acetate.
DB14541
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone cypionate.
DB14545
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone succinate.
DB14631
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone phosphate.
DB14633
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone hemisuccinate.
DB14644
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone hemisuccinate.
DB14646
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisone acetate.
DB14652
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Clocortolone acetate.
DB14659
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Melengestrol acetate.
DB14669
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Betamethasone phosphate.
DB14681
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Cortisone.
DB01013
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Clobetasol propionate.
DB01047
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocinonide.
DB14540
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Hydrocortisone butyrate.
DB00547
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Desoximetasone.
DB00764
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Mometasone.
DB08971
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluocortolone.
DB11750
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Clobetasol.
DB15566
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone acetate.
DB00324
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluorometholone.
DB09095
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Difluocortolone.
DB00159
The risk or severity of hyperkalemia can be increased when Icosapent is combined with Succinylcholine.
DB00177
The risk or severity of hyperkalemia can be increased when Valsartan is combined with Succinylcholine.
DB00187
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Succinylcholine.
DB00195
The risk or severity of hyperkalemia can be increased when Betaxolol is combined with Succinylcholine.
DB00196
The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Succinylcholine.
DB00244
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mesalazine.
DB00264
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Metoprolol.
DB00270
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Isradipine.
DB00275
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Olmesartan.
DB00328
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indomethacin.
DB00335
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Atenolol.
DB00343
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diltiazem.
DB00373
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Timolol.
DB00381
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amlodipine.
DB00384
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Triamterene.
DB00393
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nimodipine.
DB00401
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nisoldipine.
DB00407
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ardeparin.
DB00421
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spironolactone.
DB00440
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Trimethoprim.
DB00461
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nabumetone.
DB00465
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ketorolac.
DB00469
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tenoxicam.
DB00482
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Celecoxib.
DB00489
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sotalol.
DB00492
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fosinopril.
DB00500
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolmetin.
DB00519
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Trandolapril.
DB00528
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lercanidipine.
DB00533
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Rofecoxib.
DB00542
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benazepril.
DB00554
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Piroxicam.
DB00568
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cinnarizine.
DB00571
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propranolol.
DB00573
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fenoprofen.
DB00580
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Valdecoxib.
DB00584
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Enalapril.
DB00586
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diclofenac.
DB00594
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amiloride.
DB00598
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Labetalol.
DB00605
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulindac.
DB00612
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bisoprolol.
DB00678
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Losartan.
DB00691
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Moexipril.
DB00698
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nitrofurantoin.
DB00700
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Eplerenone.
DB00712
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Flurbiprofen.
DB00722
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lisinopril.
DB00738
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Pentamidine.
DB00742
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mannitol.
DB00749
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etodolac.
DB00784
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mefenamic acid.
DB00788
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Naproxen.
DB00795
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulfasalazine.
DB00796
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Candesartan cilexetil.
DB00812
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Phenylbutazone.
DB00814
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Meloxicam.
DB00821
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Carprofen.
DB00825
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Levomenthol.
DB00836
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Loperamide.
DB00861
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Diflunisal.
DB00864
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tacrolimus.
DB00876
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Eprosartan.
DB00881
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Quinapril.
DB00886
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Omapatrilat.
DB00936
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salicylic acid.
DB00939
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Meclofenamic acid.
DB00945
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acetylsalicylic acid.
DB00966
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Telmisartan.
DB00991
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Oxaprozin.
DB01009
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ketoprofen.
DB01014
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Balsalazide.
DB01015
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulfamethoxazole.
DB01023
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Felodipine.
DB01029
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Irbesartan.
DB01054
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nitrendipine.
DB01074
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Perhexiline.
DB01109
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Heparin.
DB01115
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nifedipine.
DB01118
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Amiodarone.
DB01136
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Carvedilol.
DB01167
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Itraconazole.
DB01180
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Rescinnamine.
DB01182
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propafenone.
DB01193
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acebutolol.
DB01197
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Captopril.
DB01203
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nadolol.
DB01225
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Enoxaparin.
DB01244
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bepridil.
DB01250
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Olsalazine.
DB01283
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lumiracoxib.
DB01295
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bevantolol.
DB01297
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Practolol.
DB01340
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cilazapril.
DB01342
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Forasartan.
DB01347
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Saprisartan.
DB01348
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Spirapril.
DB01349
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tasosartan.
DB01388
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mibefradil.
DB01395
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Drospirenone.
DB01397
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Magnesium salicylate.
DB01399
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salsalate.
DB01401
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Choline magnesium trisalicylate.
DB01419
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Antrafenine.
DB01424
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aminophenazone.
DB01435
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Antipyrine.
DB01600
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tiaprofenic acid.
DB01628
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etoricoxib.
DB02968
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Penicillin G Acyl-Serine.
DB03585
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Oxyphenbutazone.
DB04743
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nimesulide.
DB04812
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benoxaprofen.
DB04817
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Metamizole.
DB04825
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Prenylamine.
DB04828
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Zomepirac.
DB04838
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cyclandelate.
DB04846
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Celiprolol.
DB04861
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nebivolol.
DB04920
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Clevidipine.
DB05095
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cimicoxib.
DB05885
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Seletracetam.
DB06152
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nylidrin.
DB06212
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolvaptan.
DB06271
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sulodexide.
DB06712
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nilvadipine.
DB06725
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lornoxicam.
DB06726
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bufuralol.
DB06736
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aceclofenac.
DB06737
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Zaltoprofen.
DB06754
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Danaparoid.
DB06763
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Saralasin.
DB06767
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ammonium chloride.
DB06779
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dalteparin.
DB06822
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tinzaparin.
DB07402
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Azapropazone.
DB07615
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tranilast.
DB08439
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Parecoxib.
DB08797
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Salicylamide.
DB08807
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bopindolol.
DB08808
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bupranolol.
DB08813
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nadroparin.
DB08822
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Azilsartan medoxomil.
DB08836
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Temocapril.
DB08838
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Agmatine.
DB08907
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.
DB08940
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Kebuzone.
DB08942
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Isoxicam.
DB08951
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indoprofen.
DB08952
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indenolol.
DB08955
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ibuproxam.
DB08976
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Floctafenine.
DB08980
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fendiline.
DB08981
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fenbufen.
DB08984
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Etofenamate.
DB08991
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Epirizole.
DB09015
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canrenoic acid.
DB09026
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aliskiren.
DB09084
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benzydamine.
DB09090
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Pinaverium.
DB09204
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Arotinolol.
DB09213
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dexibuprofen.
DB09215
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Droxicam.
DB09216
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tolfenamic acid.
DB09217
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Firocoxib.
DB09218
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Clonixin.
DB09220
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nicorandil.
DB09227
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Barnidipine.
DB09229
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Aranidipine.
DB09230
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Azelnidipine.
DB09231
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benidipine.
DB09232
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cilnidipine.
DB09234
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Darodipine.
DB09235
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Efonidipine.
DB09236
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lacidipine.
DB09238
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Manidipine.
DB09239
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Niguldipine.
DB09240
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Niludipine.
DB09258
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bemiparin.
DB09259
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Reviparin.
DB09260
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Parnaparin.
DB09261
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Certoparin.
DB09279
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fimasartan.
DB09285
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Morniflumate.
DB09288
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propacetamol.
DB09295
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Talniflumate.
DB09351
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Levobetaxolol.
DB09477
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Enalaprilat.
DB11455
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Robenacoxib.
DB11466
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tepoxalin.
DB11518
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Flunixin.
DB11770
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Talinolol.
DB11783
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Imidapril.
DB11785
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Anisodamine.
DB11960
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Carboxyamidotriazole.
DB12092
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Naftopidil.
DB12097
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mannitol busulfan.
DB12212
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Landiolol.
DB12221
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canrenone.
DB12445
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nitroaspirin.
DB12545
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indobufen.
DB12752
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bucindolol.
DB12923
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Gallopamil.
DB13001
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tinoridine.
DB13166
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Zofenopril.
DB13167
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Alclofenac.
DB13217
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fentiazac.
DB13232
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Suxibuzone.
DB13286
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bumadizone.
DB13312
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Delapril.
DB13314
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Alminoprofen.
DB13371
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Difenpiramide.
DB13407
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nifenazone.
DB13432
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lonazolac.
DB13443
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Esatenolol.
DB13481
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tenidap.
DB13488
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Bencyclane.
DB13508
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cloranolol.
DB13524
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Propyphenazone.
DB13527
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Proglumetacin.
DB13530
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mepindolol.
DB13538
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Guacetisal.
DB13544
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ethenzamide.
DB13612
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Carbaspirin calcium.
DB13629
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mofebutazone.
DB13649
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Proquazone.
DB13657
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benorilate.
DB13722
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Pirprofen.
DB13725
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Terodiline.
DB13757
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Epanolol.
DB13766
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lidoflazine.
DB13775
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tertatolol.
DB13783
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Acemetacin.
DB13835
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Caroverine.
DB13860
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Imidazole salicylate.
DB13919
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Candesartan.
DB13961
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fish oil.
DB14059
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with SC-236.
DB14060
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with NS-398.
DB14063
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dexverapamil.
DB14064
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Emopamil.
DB14065
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Lomerizine.
DB14066
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Tetrandrine.
DB14068
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dexniguldipine.
DB14125
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Benazeprilat.
DB14207
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Fosinoprilat.
DB14208
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ramiprilat.
DB14213
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Perindoprilat.
DB14217
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Quinaprilat.
DB01050
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Ibuprofen.
DB09214
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Dexketoprofen.
DB00178
The risk or severity of hyperkalemia can be increased when Ramipril is combined with Succinylcholine.
DB00790
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Perindopril.
DB09212
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Loxoprofen.
DB00230
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Pregabalin.
DB04948
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lofexidine.
DB00871
The serum concentration of Succinylcholine can be increased when it is combined with Terbutaline.
DB00761
Succinylcholine may increase the hyperkalemic activities of Potassium chloride.
DB09125
Succinylcholine may increase the hyperkalemic activities of Potassium citrate.
DB11098
Succinylcholine may increase the hyperkalemic activities of Potassium bicarbonate.
DB14498
Succinylcholine may increase the hyperkalemic activities of Potassium acetate.
DB06715
Potassium Iodide may increase the hyperkalemic activities of Succinylcholine.
DB09087
Potassium alum may increase the hyperkalemic activities of Succinylcholine.
DB09413
Monopotassium phosphate may increase the hyperkalemic activities of Succinylcholine.
DB09414
Dipotassium phosphate may increase the hyperkalemic activities of Succinylcholine.
DB09418
Potassium perchlorate may increase the hyperkalemic activities of Succinylcholine.
DB09449
Sodium phosphate, monobasic may increase the hyperkalemic activities of Succinylcholine.
DB09483
Potassium lactate may increase the hyperkalemic activities of Succinylcholine.
DB11090
Potassium nitrate may increase the hyperkalemic activities of Succinylcholine.
DB11107
Potassium bitartrate may increase the hyperkalemic activities of Succinylcholine.
DB11153
Potassium hydroxide may increase the hyperkalemic activities of Succinylcholine.
DB13620
Potassium gluconate may increase the hyperkalemic activities of Succinylcholine.
DB13735
Potassium guaiacolsulfonate may increase the hyperkalemic activities of Succinylcholine.
DB13831
Potassium permanganate may increase the hyperkalemic activities of Succinylcholine.
DB13977
Potassium carbonate may increase the hyperkalemic activities of Succinylcholine.
DB14492
Potassium triiodide may increase the hyperkalemic activities of Succinylcholine.
DB14499
Potassium sulfate may increase the hyperkalemic activities of Succinylcholine.
DB14500
Potassium may increase the hyperkalemic activities of Succinylcholine.
DB01345
Succinylcholine may increase the hyperkalemic activities of Potassium cation.
DB00260
Succinylcholine may increase the neurotoxic activities of Cycloserine.
DB00361
Succinylcholine may increase the neurotoxic activities of Vinorelbine.
DB00444
Succinylcholine may increase the neurotoxic activities of Teniposide.
DB00541
Succinylcholine may increase the neurotoxic activities of Vincristine.
DB00649
Succinylcholine may increase the neurotoxic activities of Stavudine.
DB00900
Succinylcholine may increase the neurotoxic activities of Didanosine.
DB01229
Succinylcholine may increase the neurotoxic activities of Paclitaxel.
DB01294
Succinylcholine may increase the neurotoxic activities of Bismuth subsalicylate.
DB01598
Succinylcholine may increase the neurotoxic activities of Imipenem.
DB09154
Succinylcholine may increase the neurotoxic activities of Sodium citrate.
DB09275
Succinylcholine may increase the neurotoxic activities of Bismuth subcitrate potassium.
DB11281
Succinylcholine may increase the neurotoxic activities of Bismuth subcarbonate.
DB13209
Succinylcholine may increase the neurotoxic activities of Bismuth subnitrate.
DB13909
Succinylcholine may increase the neurotoxic activities of Bismuth subgallate.
DB13910
Succinylcholine may increase the neurotoxic activities of Valproate bismuth.
DB00781
Succinylcholine may increase the neurotoxic activities of Polymyxin B.
DB15965
Succinylcholine may increase the neurotoxic activities of Naxitamab.
DB05077
The risk or severity of adverse effects can be increased when SLV319 is combined with Succinylcholine.
DB06155
The risk or severity of adverse effects can be increased when Rimonabant is combined with Succinylcholine.
DB06624
The risk or severity of adverse effects can be increased when Taranabant is combined with Succinylcholine.
DB09061
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Succinylcholine.
DB11903
The risk or severity of adverse effects can be increased when GW842166 is combined with Succinylcholine.
DB12193
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Succinylcholine.
DB12649
The risk or severity of adverse effects can be increased when Ibipinabant is combined with Succinylcholine.
DB13070
The risk or severity of adverse effects can be increased when Surinabant is combined with Succinylcholine.
DB13950
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Succinylcholine.
DB14011
The risk or severity of adverse effects can be increased when Nabiximols is combined with Succinylcholine.
DB14043
The risk or severity of adverse effects can be increased when Palmidrol is combined with Succinylcholine.
DB14737
The risk or severity of adverse effects can be increased when Cannabinol is combined with Succinylcholine.
DB11537
The risk or severity of neuromuscular blockade can be increased when Pirlimycin is combined with Succinylcholine.
DB01026
The therapeutic efficacy of Ketoconazole can be increased when used in combination with Succinylcholine.
DB00911
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Tinidazole.
DB00916
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Metronidazole.
DB01110
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Miconazole.
DB13026
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Ornidazole.
DB13319
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Propenidazole.
DB14507
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lithium citrate.
DB14509
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lithium carbonate.
DB14506
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lithium hydroxide.
DB00762
The serum concentration of Irinotecan can be increased when it is combined with Succinylcholine.
DB01116
The serum concentration of Trimethaphan can be increased when it is combined with Succinylcholine.
DB01161
The serum concentration of Chloroprocaine can be increased when it is combined with Succinylcholine.
DB01364
The serum concentration of Ephedrine can be increased when it is combined with Succinylcholine.
DB05875
The serum concentration of Sar9, Met (O2)11-Substance P can be increased when it is combined with Succinylcholine.
DB08893
The serum concentration of Mirabegron can be increased when it is combined with Succinylcholine.
DB09205
The serum concentration of Moxisylyte can be increased when it is combined with Succinylcholine.
DB04250
The serum concentration of Butyrylthiocholine can be increased when it is combined with Succinylcholine.
DB00892
The serum concentration of Oxybuprocaine can be increased when it is combined with Succinylcholine.
DB11823
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Esketamine.
DB00395
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Succinylcholine.
DB00181
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Baclofen.
DB00390
Succinylcholine may increase the arrhythmogenic activities of Digoxin.
DB13401
Succinylcholine may increase the arrhythmogenic activities of Metildigoxin.
DB13691
Succinylcholine may increase the arrhythmogenic activities of Acetyldigoxin.
DB00402
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Eszopiclone.
DB00575
The risk or severity of sedation can be increased when Clonidine is combined with Succinylcholine.
DB00924
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Cyclobenzaprine.
DB01233
The risk or severity of sedation can be increased when Metoclopramide is combined with Succinylcholine.
DB11732
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lasmiditan.
DB00695
Furosemide may increase the skeletal muscle relaxing activities of Succinylcholine.
DB00193
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tramadol.
DB01190
The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Succinylcholine.
DB00246
The risk or severity of adverse effects can be increased when Succinylcholine is combined with Ziprasidone.
DB14513
Magnesium can cause a decrease in the absorption of Succinylcholine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00502
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Haloperidol.
DB00472
Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
DB12404
The risk or severity of sedation can be increased when Succinylcholine is combined with Remimazolam.
DB14881
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Succinylcholine is combined with Oliceridine.

序列

实验性质

外部标识符

resource：Drugs Product Database (DPD)
identifier：8833
resource：ChEBI
identifier：45652
resource：PubChem Compound
identifier：5314
resource：PubChem Substance
identifier：46506023
resource：KEGG Compound
identifier：C07546
resource：ChemSpider
identifier：5123
resource：BindingDB
identifier：50061568
resource：PharmGKB
identifier：PA451522
resource：PDB
identifier：SCK
resource：Therapeutic Targets Database
identifier：DAP001132
resource：IUPHAR
identifier：4004
resource：Guide to Pharmacology
identifier：4004
resource：Wikipedia
identifier：Suxamethonium_chloride
resource：ChEMBL
identifier：CHEMBL703
resource：ZINC
identifier：ZINC000001530820
resource：RxCUI
identifier：10154

外部链接

RxList
http://www.rxlist.com/cgi/generic2/succinyl.htm
Drugs.com
http://www.drugs.com/cdi/succinylcholine.html

路径

目标

id:BE0000411
name:Neuronal acetylcholine receptor subunit alpha-10
organism:Humans
action:agonist
Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI: Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology. 2006 Apr;104(4):724-33.
known-action:yes
name:Neuronal acetylcholine receptor subunit alpha-10
general-function:Receptor binding
specific-function:Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.
gene-name:CHRNA10
locus:11p15.5
cellular-location:Cell junction
transmembrane-regions:238-258 268-288 302-322 429-449
signal-regions:1-24
theoretical-pi:7.97
molecular-weight:49704.295
chromosome-location:11
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:13800GenAtlasCHRNA10GenBank Gene DatabaseAJ278118GenBank Protein Database12053839IUPHAR470Guide to Pharmacology470UniProtKBQ9GZZ6UniProt AccessionACH10_HUMAN
synonyms:NACHR alpha-10NACHRA10Nicotinic acetylcholine receptor subunit alpha-10
amino-acid-sequence:>lcl|BSEQ0010285|Neuronal acetylcholine receptor subunit alpha-10 MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLE VTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYN KADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGH QLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYV CNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGK YYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQS RPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWK RLARVMDRFFLAIFFSMALVMSLLVLVQAL
gene-sequence:>lcl|BSEQ0010286|Neuronal acetylcholine receptor subunit alpha-10 (CHRNA10) ATGCCGGCGCGGCGGCGCGTGCTCACCTACGGCTGCTGCTCCGAGCCCTACCCCGACGTC ACCTTCACGCTGCTGCTGCGCCGCCGCGCCGCCGCCTACGTGTGCAACCTGCTGCTGCCC TGCGTGCTCATCTCGCTGCTTGCGCCGCTCGCCTTCCACCTGCCTGCCGACTCAGGCGAG AAGGTGTCGCTGGGCGTCACCGTGCTGCTGGCGCTCACCGTCTTCCAGTTGCTGCTGGCC GAGAGCATGCCACCGGCCGAGAGCGTGCCGCTCATCGGGAAGTACTACATGGCCACTATG ACCATGGTCACATTCTCAACAGCACTCACCATCCTTATCATGAACCTGCATTACTGTGGT CCCAGTGTCCGCCCAGTGCCAGCCTGGGCTAGGGCCCTCCTGCTGGGACACCTGGCACGG GGCCTGTGCGTGCGGGAAAGAGGGGAGCCCTGTGGGCAGTCCAGGCCACCTGAGTTATCT CCTAGCCCCCAGTCGCCTGAAGGAGGGGCTGGCCCCCCAGCGGGCCCTTGCCACGAGCCA CGATGTCTGTGCCGCCAGGAAGCCCTACTGCACCACGTAGCCACCATTGCCAATACCTTC CGCAGCCACCGAGCTGCCCAGCGCTGCCATGAGGACTGGAAGCGCCTGGCCCGTGTGATG GACCGCTTCTTCCTGGCCATCTTCTTCTCCATGGCCCTGGTCATGAGCCTCCTGGTGCTG GTGCAGGCCCTGTGA
pfams:PF02931Neur_chan_LBDPF02932Neur_chan_memb
go-classifiers:componentacetylcholine-gated channel complexcomponentaxoncomponentcell junctioncomponentcytosolcomponentmembranecomponentneuron projectioncomponentperikaryoncomponentpostsynaptic membranecomponentsynapsefunctionacetylcholine-activated cation-selective channel activityfunctioncalcium channel activityfunctionreceptor bindingprocesscation transmembrane transportprocessdetection of mechanical stimulus involved in sensory perception of soundprocessinner ear morphogenesisprocessneurological system processprocessneuromuscular synaptic transmissionprocesspositive regulation of cytosolic calcium ion concentrationprocessregulation of cell proliferationprocessregulation of membrane potentialprocessresponse to nicotineprocesssignal transductionprocesssynaptic transmission, cholinergic
id:BE0003438
name:Alpha-7 nicotinic cholinergic receptor subunit
organism:Humans
action:agonist
Rogers KR, Fernando JC, Thompson RG, Valdes JJ, Eldefrawi ME: Detection of nicotinic receptor ligands with a light addressable potentiometric sensor. Anal Biochem. 1992 Apr;202(1):111-6.
Fiacchino F, Ariano C, Gemma M, Cerrato D: Abnormal responses to succinylcholine and pancuronium in a patient with hemiparesis. Ital J Neurol Sci. 1990 Oct;11(5):497-9.
Marshall CG, Ogden DC, Colquhoun D: The actions of suxamethonium (succinyldicholine) as an agonist and channel blocker at the nicotinic receptor of frog muscle. J Physiol. 1990 Sep;428:155-74.
known-action:yes
name:Alpha-7 nicotinic cholinergic receptor subunit
general-function:
specific-function:
gene-name:CHRNA7
locus:
cellular-location:
transmembrane-regions:
signal-regions:1-22
theoretical-pi:3.55
molecular-weight:2987.635
chromosome-location:
organism:Humans
external-identifiers:GenAtlasCHRFAM7AGenBank Gene DatabaseAY641831UniProtKBQ693P7UniProt AccessionQ693P7_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0022322|Alpha-7 nicotinic cholinergic receptor subunit ITVLLSLTVFMLLVAEIMPATSDSVPLI
gene-sequence:>lcl|BSEQ0006706|87 bp GGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCTGAGATCATGCCCG CAACATCCGATTCGGTACCATTGATAG
pfams:PF02932Neur_chan_memb
go-classifiers:componentintegral component of membraneprocession transport
id:BE0000092
name:Muscarinic acetylcholine receptor M1
organism:Humans
action:agonist
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
Fisher DM: Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm. 1999 Jun 1;56(11 Suppl 1):S4-9.
known-action:yes
name:Muscarinic acetylcholine receptor M1
general-function:Phosphatidylinositol phospholipase c activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
gene-name:CHRM1
locus:11q13
cellular-location:Cell membrane
transmembrane-regions:25-47 62-82 100-121 142-164 187-209 367-387 402-421
signal-regions:
theoretical-pi:9.67
molecular-weight:51420.375
chromosome-location:11
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1950GenAtlasCHRM1GenBank Gene DatabaseX52068GenBank Protein Database34451IUPHAR13Guide to Pharmacology13UniProtKBP11229UniProt AccessionACM1_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0000184|Muscarinic acetylcholine receptor M1 MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVN NYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLIS FDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYI QFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSS SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEV VIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKE KKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC
gene-sequence:>lcl|BSEQ0009929|Muscarinic acetylcholine receptor M1 (CHRM1) ATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG GGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG ACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT AACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC CTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC TGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC TTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC CGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC ATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC CAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT GTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG GAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC TCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT CGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG GACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG GTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG AGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC CAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG AAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG TACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG GAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC TGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA CGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC TGA
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentmembranecomponentplasma membranecomponentpostsynaptic densitycomponentpostsynaptic membranecomponentsynapsefunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityfunctionphosphatidylinositol phospholipase C activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocesscell proliferationprocesscellular protein modification processprocesscognitionprocessentrainment of circadian clockprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnervous system developmentprocessneuromuscular synaptic transmissionprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocessphototransduction, visible lightprocesspositive regulation of cell proliferationprocesspositive regulation of intracellular protein transportprocesspositive regulation of ion transportprocessprotein kinase C-activating G-protein coupled receptor signaling pathwayprocessregulation of locomotionprocesssaliva secretionprocesssensory perception of chemical stimulusprocesssignal transductionprocesssynaptic transmission, cholinergic
id:BE0000560
name:Muscarinic acetylcholine receptor M2
organism:Humans
action:agonist
Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50.
known-action:unknown
name:Muscarinic acetylcholine receptor M2
general-function:G-protein coupled acetylcholine receptor activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.
gene-name:CHRM2
locus:7q31-q35
cellular-location:Cell membrane
transmembrane-regions:23-45 60-80 98-119 140-162 185-209 388-410 419-442
signal-regions:
theoretical-pi:9.08
molecular-weight:51714.605
chromosome-location:7
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1951GenAtlasCHRM2GenBank Gene DatabaseM16404GenBank Protein Database177990IUPHAR14Guide to Pharmacology14UniProtKBP08172UniProt AccessionACM2_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0016133|Muscarinic acetylcholine receptor M2 MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR
gene-sequence:>lcl|BSEQ0016134|Muscarinic acetylcholine receptor M2 (CHRM2) ATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA TTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG AACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC TTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC ACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA GCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC AGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA GGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC TTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT TTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC ATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC AAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA GTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC CAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG GAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA ATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT AAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT AATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT GTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC CGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG GCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT GTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT GCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG AACATAGGCGCTACAAGGTAA
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentneuronal cell bodycomponentplasma membranecomponentpostsynaptic membranecomponentsymmetric synapsecomponentsynapsefunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessnervous system developmentprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocessregulation of heart contractionprocessregulation of smooth muscle contractionprocessresponse to virusprocesssensory perception of chemical stimulusprocesssynaptic transmission, cholinergic
id:BE0000045
name:Muscarinic acetylcholine receptor M3
organism:Humans
action:agonist
Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. Anesthesiology. 1998 Mar;88(3):744-50.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
known-action:unknown
name:Muscarinic acetylcholine receptor M3
general-function:Receptor activity
specific-function:The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
gene-name:CHRM3
locus:1q43
cellular-location:Cell membrane
transmembrane-regions:68-91 105-130 143-164 185-206 230-252 492-514 527-546
signal-regions:
theoretical-pi:9.62
molecular-weight:66127.445
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1952GenAtlasCHRM3GenBank Gene DatabaseX15266GenBank Protein Database32324IUPHAR15Guide to Pharmacology15UniProtKBP20309UniProt AccessionACM3_HUMAN
synonyms:
amino-acid-sequence:>lcl|BSEQ0009898|Muscarinic acetylcholine receptor M3 MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL
gene-sequence:>lcl|BSEQ0009899|Muscarinic acetylcholine receptor M3 (CHRM3) ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG
pfams:PF000017tm_1
go-classifiers:componentasymmetric synapsecomponentaxon terminuscomponentbasolateral plasma membranecomponentcell junctioncomponentdendritecomponentintegral component of plasma membranecomponentplasma membranecomponentpostsynaptic membranecomponentsynapsefunctionacetylcholine bindingfunctiondrug bindingfunctionG-protein coupled acetylcholine receptor activityfunctionphosphatidylinositol phospholipase C activityfunctionreceptor activityprocessadenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathwayprocesscell proliferationprocesscellular protein modification processprocessenergy reserve metabolic processprocessG-protein coupled acetylcholine receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnervous system developmentprocessphospholipase C-activating G-protein coupled acetylcholine receptor signaling pathwayprocesspositive regulation of smooth muscle contractionprocessregulation of insulin secretionprocessregulation of vascular smooth muscle contractionprocesssaliva secretionprocesssensory perception of chemical stimulusprocesssignal transductionprocesssmall molecule metabolic processprocesssmooth muscle contractionprocesssynaptic transmission, cholinergic

酶

BE0002180CholinesteraseHumanssubstrateA150832682131Ostergaard D, Engbaek J, Viby-Mogensen J: Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68.unknownCholinesteraseIdentical protein bindingEsterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.BCHE3q26.1-q26.2Secreted1-287.4768417.5753HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:983GenAtlasBCHEGenBank Gene DatabaseM32391GenBank Protein Database1311630Guide to Pharmacology2471UniProtKBP06276UniProt AccessionCHLE_HUMAN3.1.1.8Acylcholine acylhydrolaseButyrylcholine esteraseCHE1Choline esterase IIPseudocholinesterase>lcl|BSEQ0016706|Cholinesterase MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV GL>lcl|BSEQ0016707|Cholinesterase (BCHE) ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG GGTCTCTAAPF00135COesterasePF08674AChE_tetracomponentblood microparticlecomponentendoplasmic reticulum lumencomponentextracellular regioncomponentmembranecomponentnuclear envelope lumenfunctionacetylcholinesterase activityfunctionbeta-amyloid bindingfunctioncatalytic activityfunctioncholine bindingfunctioncholinesterase activityfunctionenzyme bindingfunctionidentical protein bindingprocessacetylcholine catabolic processprocesscellular protein metabolic processprocesscholine metabolic processprocesscocaine metabolic processprocesslearningprocessnegative regulation of cell proliferationprocessnegative regulation of synaptic transmissionprocessneuroblast differentiationprocessresponse to alkaloidprocessresponse to drugprocessresponse to folic acidprocessresponse to glucocorticoidprocesssynaptic transmission

载体

运输工具

药物反应

效应

不良反应